Up 38.5% in One Year, Exosens Stock Advances 2% During Trading Session
The Bordeaux-based optronic company reclaims its position in the upper ranks of the SBF 120 while the index declines. The stock thus emerges from the pullback zone that had characterized the end of last week.
A Rebound That Brings the Price Back Above the 20-Day, 50-Day and 200-Day Moving Averages
Exosens stock gains 2.03% to €60.40 in early afternoon trading, moving against the grain of a SBF 120 that yields 0.5%. This movement places it at the 12th position on the index for the session. The stock moves back above its three moving averages: the 20-day MA at €58.69 (spread of 2.91%), the 50-day MA at €60.00 (spread of 0.67%) and the 200-day MA at €59.73.
The price is only 0.67% from the 50-day MA and 1.12% from the 200-day MA, meaning that these two thresholds remain close to the current price. The RSI at 48 is neutral. Over seven days, the stock remains down 3.05%, but it shows +9.42% over one month.
A Series of Analyst Opinions and Target Price Increases That Preceded the Rebound
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The group had raised its annual targets on September 17, with revenue targeted up to €570 million and adjusted EBITDA growth of approximately 25% in 2026. The stock surged nearly 10% that day. Bernstein subsequently raised its price target to €74 on September 23, but the stock retreated 3.5% the following day, then lost ground on September 25.
Support is found at €54.15 and resistance at €63.40, which is 5% above the current price. Results for the first nine months are expected on October 27.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
